Clinical Trial Tests CAR T-Cell Therapy on Peritoneal Mesothelioma

The National Cancer Institute in Rockville, Maryland, has opened an innovative clinical trial for patients with peritoneal mesothelioma that will explore the safety and effectiveness of a novel CAR T-cell therapy. The phase I trial also is being conducted at Washington University in St. Louis. It is aimed at patients whose disease has relapsed after initial chemotherapy treatment. It involves a laboratory modification of a patient's T cells — a type of white blood cell — that can help the immune system kill the cancer. CAR T-cell therapy is a form of gene therapy that has been highly successful with blood and bone marrow cancers. The U.S. Food and Drug Administration first approved the therapy in 2017 for pediatric leukemia. "If it works well here, it could change the way [periton...

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2S9OJgm